Health economic assessment of universal immunization of toddlers against Hepatitis A Virus (HAV) in Mexico.
Hepatitis A virus (HAV) has shifted from high to intermediate endemicity in Mexico, which may increase the risk of clinically significant HAV infections in older children, adolescents and adults. The objective of this study was to evaluate the cost-utility of single-dose or 2-dose universal infant HAV vaccination strategy in Mexico, compared with no vaccination. A previously published dynamic model estimated the expected number of HAV cases with each strategy, and a decision model was used to estimate the costs and quality-adjusted life-years (QALYs) expected with each strategy. The time horizon was 25 years (2012-2036) and the base case analysis was conducted from the perspective of the Mexican public health system. Costs and QALYs after the first year were discounted at 5% annually. Input data were taken from national databases and published sources where available. The single-dose HAV vaccination strategy had an incremental cost-utility ratio (ICUR) of Mexican peso (MXN) 2,270 per QALY gained, compared with no vaccination. The two-dose strategy had an ICUR of MXN 14,961/QALY compared with no vaccination, and an ICUR of MXN 78,280/QALY compared with the single-dose strategy. The estimated ICURs were below the threshold of 1 x Mexican gross domestic product per capita. When indirect costs were included (societal perspective), the single-dose HAV vaccination strategy would be expected to improve health outcomes and to be cost-saving. This analysis indicates that routine vaccination of toddlers against HAV would be cost-effective in Mexico using either a single-dose or a 2-dose vaccination strategy. GSK study identifier: HO-12-12877.
a R A C Salud Consultores, S.A. de C.V. ; Ciudad de México , Mexico.
Fernando
F
Carlos
b Epidemiology Latam; GlaxoSmithKline, Argentina ; Victoria, Buenos Aires , Argentina.
Jorge Alberto
JA
Gómez
c GlaxoSmithKline ; Ciudad de México , México.|d IMS Health Latin America ; Ciudad de México , Mexico.
Pablo
P
Anaya
c GlaxoSmithKline ; Ciudad de México , México.
Luis
L
Romano-Mazzotti
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D003362:Cost-Benefit Analysis; D005260:Female; D006506:Hepatitis A / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D022362:Hepatitis A Vaccines / Q000008:administration & dosage / Q000191:economics* / Q000276:immunology*; D006801:Humans; D007223:Infant; D008297:Male; D008800:Mexico / Q000453:epidemiology; D008875:Middle Aged; D011788:Quality of Life; D014611:Vaccination / Q000191:economics*; D055815:Young Adult
D022362:Hepatitis A Vaccines
Mexico; cost-effectiveness; economic evaluation; hepatitis A; vaccination